This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity/Overweight

Launched by ASTRAZENECA · Jun 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new treatments for people who are living with obesity or being overweight. Specifically, the researchers want to understand how safe and effective two medications, AZD6234 and AZD9550, are when used alone or together. The study involves participants from multiple locations in China and is currently looking for individuals between the ages of 18 and 55 who have a body mass index (BMI) of 27 or higher. To ensure safety, participants should have maintained a stable weight for at least three months before joining and must not have taken any weight-loss medications recently.

If you decide to join this trial, you will be closely monitored to assess how well the treatments work and how well you tolerate them. It’s important to note that certain health conditions, like diabetes or significant liver problems, may prevent someone from participating. Additionally, women who are pregnant or breastfeeding cannot join the study. Overall, this trial aims to gather valuable information that could help develop better treatments for obesity, which is a growing health issue.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 to 55 years.
• • 2. BMI ≥ 27 kg/m2.
• • 3. Stable body weight for 3 months prior to screening.
• • 4. Male and female (Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
• • 5. Participants should refrain from blodd donation throughout the sub-study, including the follow-up period.
• • 6. Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding.
• Exclusion Criteria:
• • 1. Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening.
• • 2. History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control.
• • 3. Treatment with diabetes medication in past 3 months prior to screening.
• • 4. HbA1c ≥ 6.5% (48 mmol/mol) at screening.
• • 5. Gastroparesis (or similar) requiring treatment.
• • 6. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract.
• 7. Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:
• • 1. AST ≥ 2.5 × ULN
• • 2. ALT ≥ 2.5 × ULN
• • 3. TBL ≥ 1.5 × ULN.
• • 8. Prior history of cholecystectomy or untreated cholelithiasis.
• • 9. History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening.
• • 10. Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes.
• • 11. HR \< 50 bpm or \> 100 bpm after being at rest for 5 minutes.
• • 12. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI).
• • 13. History of psychosis or bipolar disorder.
• • 14. Severe vitamin D deficiency defined as a 25-OH vitamin D level \< 12 ng/mL.
• • 15. Uncontrolled thyroid disease, defined as TSH \> ULN or \< LLN for the laboratory reference range, as judged by the PI at screening.